These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26572486)

  • 1. NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease.
    Devi CS; Mohanasrinivasan V; Priyadoss CG; Arora N; Singh B; Mittal N; Agarwal S; Saxena S
    Curr Drug Discov Technol; 2015; 12(4):214-7. PubMed ID: 26572486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
    Bhattacharya S; Haertel C; Maelicke A; Montag D
    PLoS One; 2014; 9(2):e89454. PubMed ID: 24586789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms.
    Halliday G; Robinson SR; Shepherd C; Kril J
    Clin Exp Pharmacol Physiol; 2000; 27(1-2):1-8. PubMed ID: 10696521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B; Haen E
    Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice.
    Bhattacharya S; Maelicke A; Montag D
    J Alzheimers Dis; 2015; 46(1):123-36. PubMed ID: 25720404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model.
    Zhai Y; Yamashita T; Nakano Y; Sun Z; Shang J; Feng T; Morihara R; Fukui Y; Ohta Y; Hishikawa N; Abe K
    J Alzheimers Dis; 2016 Jun; 53(3):893-905. PubMed ID: 27314529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease.
    Huang XT; Qian ZM; He X; Gong Q; Wu KC; Jiang LR; Lu LN; Zhu ZJ; Zhang HY; Yung WH; Ke Y
    Neurobiol Aging; 2014 May; 35(5):1045-54. PubMed ID: 24332448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the acetylcholinesterase inhibitor galanthamine.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2393-402. PubMed ID: 11060814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development.
    Cutler NR; Sramek JJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Jan; 25(1):27-57. PubMed ID: 11263756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease.
    Ozben T; Ozben S
    Clin Biochem; 2019 Oct; 72():87-89. PubMed ID: 30954437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
    Martinez A; Castro A
    Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!
    Tabet N
    Age Ageing; 2006 Jul; 35(4):336-8. PubMed ID: 16788077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
    Wang CH; Wang LS; Zhu N
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4801-4817. PubMed ID: 27906438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for Alzheimer's disease.
    Ritter JM
    Br J Clin Pharmacol; 2012 Apr; 73(4):501-3. PubMed ID: 22409497
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy against amyloid pathology in Alzheimer's disease.
    Galimberti D; Ghezzi L; Scarpini E
    J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.